Auditory Restoration and Outcomes After Gene Therapy and Cochlear Implantation: a PRospective Cohort Analysis (AURORA)
A legfontosabb adatok
- Ki végzi
- Eye & ENT Hospital of Fudan University
- Hol
- Kína6 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toboroz
- Résztvevők
- 180 fő, tervezett
- Kezdés
- 2024. ápr. 6.
- Várható befejezés
- 2029. dec. 22.
- A vizsgálat típusa
- Megfigyeléses, 2 csoport
- A regiszteradat frissítve
- 2026. augusztus 31.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for people with hearing loss from birth who have had or plan to have gene therapy, or who get a cochlear implant. It also takes healthy people with normal hearing of similar age and sex.
- Életkor
- 6 months and older.
- Nem
- All sexes can join.
- A betegség stádiuma
- Hearing loss from birth with hearing thresholds ≥65 dB. Healthy people need normal hearing in both ears (≤20 dB).
- Korábbi kezelés
- Patients must have had, or plan to have, gene therapy with standard rehabilitation and follow-up, or have cochlear implant surgery.
- Biomarker vagy leletérték
- The gene therapy group must have a confirmed diagnosis of autosomal recessive deafness 9 (DFNB9).
A részvétel fő kizáró okai
- Other ear problems, such as malformed middle or inner ear, hearing nerve problems, ear infections or Meniere's disease.
- Other severe birth conditions, or severe or acute illnesses such as tuberculosis, active hepatitis B or C, or kidney problems.
- Weak immune system, immune deficiency or a past organ transplant.
- Past neurological or mental disorders, such as epilepsy or dementia.
- Cannot safely have surgery or anesthesia, for example a heart or brain blood vessel event in the past 6 months.
A regiszter feltételei, szó szerint
Mind a 11 feltétel megnézéseKevesebb
Ki vehet részt
- Patients with congenital hearing loss with hearing thresholds ≥65 dB receive either gene therapy (previously received gene therapy and standardized postoperative rehabilitation and follow-up or plan to receive gene therapy), or cochlear implant surgery. Healthy participants with bilateral hearing thresholds within the normal range (≤20 dB), generally matched to the gene therapy group and the cochlear implant group by age and sex
- Age ≥ 6 months, regardless of gender. Mandarin Chinese as the native language. Participants and their guardians must provide informed consent before the trial, voluntarily sign a written consent form, and commit to follow-up at specified time points
- Capable of effective communication with researchers with the assistance of their guardians and willing to cooperate and comply with the researchers' requirements
- The participant's guardians should have a correct understanding of the trial and appropriate expectations regarding potential benefits
Ki nem vehet részt
- Presence of other otological disorders that may interfere with the surgical outcome or interpretation of study endpoints, such as middle/inner ear dysplasia or malformations revealed by CT/MRI scans performed within the past 3 months that may affect the therapeutic effect, vestibular-cochlear nerve abnormalities, acute/chronic otitis media, Meniere's disease, etc
- Presence of other severe congenital diseases. Presence of severe systemic diseases or diseases in the acute phase, such as pulmonary tuberculosis, active hepatitis B or C infection, active herpes zoster infection, pancreatitis, renal insufficiency, etc
- Individuals with low immunity, a history of immune deficiency or organ transplantation
- Individuals with a history of neurological or mental disorders, such as epilepsy or dementia
- Patients with contraindications to surgery or anesthesia, as assessed by a surgeon, anesthetist, or designated personnel, such as cardiovascular or cerebrovascular events in the past 6 months, allergies to the planned medications, etc
- Gene therapy group: gene therapy did not restore hearing; Cochlear implant group: presence of hereditary syndromic deafness or other conditions that seriously affect the efficacy evaluation
- Any other conditions for which the investigators consider the subject unsuitable for participation in this clinical study
Ez a vizsgálat jelenleg itt érhető el: Kína.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
This cohort study aims to explore the trends and differences in multidimensional perceptual levels of patients after cochlear implants or gene therapy, as well as to comprehensively assess the efficacy of gene therapy for congenital deafness, thus providing a reference for making a well-rounded postoperative rehabilitation protocol for gene therapy patients.
A vizsgálat 2 csoportja
- Gene Therapy Group
The study will recruit gene therapy patients who are definitely diagnosed with autosomal recessive deafness 9 (DFNB9).
- Cochlear Implant Group
The study will recruit cochlear implant patients with congenital deafness.
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- A regiszteradat frissítve
- 2026. augusztus 31.